Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Coverage topic
No spam. Unsubscribe anytime.
Committee recommends removing GLP‑1 weight‑loss coverage after three‑year review
Summary
Benefits consultant told the committee county spending on GLP‑1 medications for weight‑loss has grown to roughly $2.5 million annually and the number of members on those drugs rose by about 100 last year; she recommended removing coverage for weight‑loss uses while preserving coverage for medically necessary uses such as diabetes.
Marissa Combs Smith of Gallagher recommended that Rutherford County remove coverage of GLP‑1 medications when prescribed solely for weight loss, citing a sharp and sustained increase in pharmacy spend tied to those drugs.
"The spend... has now reached around 2,500,000 in annual cost," Combs Smith told the committee, and she said membership on the drug class had increased by about 100 people over the previous year from roughly 295. She said Gallagher had monitored utilization for about three years and concluded the trend was unlikely to reverse without a policy change.
Combs Smith emphasized the recommendation would not affect patients with medically necessary indications such as diabetes. "It is our expectation... that those with the diagnosis code of diabetes who are also on this medication would not be affected," she said. Members asked whether administrating claims engines would require renewed documentation and whether removing coverage would raise other costs; Combs Smith and staff said prior authorization and claims administration steps would still be used to ensure appropriate prescribing.
The committee debated alternatives including entry limits, recertification requirements and specialty out-of-pocket options, but the consultant said those approaches also carry costs and administrative work. The change is part of the broader bundled motion the committee approved to forward 2027 plan design changes and rates.
